Platinum exposure and cause-specific mortality among patients with testicular cancer
Autor: | Ronald de Wit, Sjoukje Lubberts, Michael Schaapveld, O. W. M. Meijer, Simon Horenblas, Igle J. de Jong, Tineke J. Smilde, Alexandra W. van den Belt-Dusebout, Jourik A. Gietema, Hetty A van den Berg, Ben G. L. Vanneste, Gerard Groenewegen, Maarten C.C.M. Hulshof, Maureen J.B. Aarts, Harmke J. Groot, Katarzyna Jóźwiak, Philip Poortmans, J. Alfred Witjes, Flora E. van Leeuwen |
---|---|
Přispěvatelé: | Radiotherapie, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), Radiation Oncology, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Radiotherapy, CCA - Cancer Treatment and Quality of Life, Medical Oncology |
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
Male
Cancer Research medicine.medical_treatment cause‐specific mortality cisplatin Gastroenterology Cohort Studies 0302 clinical medicine GERM-CELL CANCER Risk Factors Cause of Death Epidemiology 030212 general & internal medicine platinum RISK education.field_of_study Mortality rate THROMBOEMBOLIC EVENTS Hazard ratio LONG-TERM SURVIVORS Neoplasms Second Primary Middle Aged CHEMOTHERAPY Women's cancers Radboud Institute for Health Sciences [Radboudumc 17] testicular cancer Oncology CARDIOVASCULAR-DISEASE 030220 oncology & carcinogenesis Cohort Original Article Female epidemiology Adult medicine.medical_specialty cause-specific mortality Population Antineoplastic Agents Discipline Young Adult 03 medical and health sciences Testicular Neoplasms SDG 3 - Good Health and Well-being Internal medicine Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15] medicine Humans 2ND CANCERS education Testicular cancer Proportional Hazards Models Chemotherapy Bladder cancer CHILDHOOD-CANCER business.industry Original Articles medicine.disease MYOCARDIAL-INFARCTION business survivorship |
Zdroj: | Cancer, 126(3), 628-639. Wiley Cancer, 126(3), 628-639. John Wiley and Sons Inc. Cancer, 126, 628-639 Groot, H J, van Leeuwen, F E, Lubberts, S, Horenblas, S, de Wit, R, Witjes, J A, Groenewegen, G, Poortmans, P M, Hulshof, M C C M, Meijer, O W M, de Jong, I J, van den Berg, H A, Smilde, T J, Vanneste, B G L, Aarts, M J B, Jóźwiak, K, van den Belt-Dusebout, A W, Gietema, J A & Schaapveld, M 2020, ' Platinum exposure and cause-specific mortality among patients with testicular cancer ', Cancer, vol. 126, no. 3, pp. 628-639 . https://doi.org/10.1002/cncr.32538 Cancer, 126(3), 628. John Wiley and Sons Inc. Cancer, 126, 3, pp. 628-639 Cancer, 126, 628-639. John Wiley & Sons Inc. Cancer |
ISSN: | 0008-543X |
Popis: | Background Although testicular cancer (TC) treatment has been associated with severe late morbidities, including second malignant neoplasms (SMNs) and ischemic heart disease (IHD), cause‐specific excess mortality has been rarely studied among patients treated in the platinum era. Methods In a large, multicenter cohort including 6042 patients with TC treated between 1976 and 2006, cause‐specific mortality was compared with general population mortality rates. Associations with treatment were assessed with proportional hazards analysis. Results With a median follow‐up of 17.6 years, 800 patients died; 40.3% of these patients died because of TC. The cumulative mortality was 9.6% (95% confidence interval [CI], 8.5%‐10.7%) 25 years after TC treatment. In comparison with general population mortality rates, patients with nonseminoma experienced 2.0 to 11.6 times elevated mortality from lung, stomach, pancreatic, rectal, and kidney cancers, soft‐tissue sarcomas, and leukemia; 1.9‐fold increased mortality (95% CI, 1.3‐2.8) from IHD; and 3.9‐fold increased mortality (95% CI, 1.5‐8.4) from pneumonia. Seminoma patients experienced 2.5 to 4.6 times increased mortality from stomach, pancreatic, bladder cancer and leukemia. Radiotherapy and chemotherapy were associated with 2.1 (95% CI, 1.8‐2.5) and 2.5 times higher SMN mortality (95% CI, 2.0‐3.1), respectively, in comparison with the general population. In a multivariable analysis, patients treated with platinum‐containing chemotherapy had a 2.5‐fold increased hazard ratio (HR; 95% CI, 1.8‐3.5) for SMN mortality in comparison with patients without platinum‐containing chemotherapy. The HR for SMN mortality increased 0.29 (95% CI, 0.19‐0.39) per 100 mg/m2 platinum dose administered (P trend Platinum‐containing chemotherapy is associated with a dose‐dependent increase in the risk of cancer mortality among patients with testicular cancer. Patients with testicular cancer experience increased mortality from second malignancies as well as causes other than cancer, particularly ischemic heart diseases. |
Databáze: | OpenAIRE |
Externí odkaz: |